アブストラクト | BACKGROUND: Romosozumab is a novel drug for the treatment of osteoporosis. The adverse reactions of romosozumab still need to be explored. The FDA Adverse Event Reporting System (FAERS) provides an enormous dataset for adverse events (AEs) analysis. RESEARCH DESIGN AND METHODS: AEs registered in FAERS between January 2019 and December 2020 were collected for this study. The reporting odds ratio (ROR) method was applied to analyze the AEs of romosozumab. The number of AEs >/=4 cases and ROR value 95% confidence interval (CI) lower limit >1 was considered statistically significant. RESULTS: A total of 4,413,695 AEs were collected for this study. There were 1,948 AEs related with romosozumab reported in FAERS. There are 1851 AEs including 17 system classifications after filtered. Injection site pain (ROR = 6.89, CI = 5.60, 8.48), cardiac failure (ROR = 12.62, CI = 9.85, 16.17), renal impairment (ROR = 9.11, CI = 6.98, 11.89), pneumonia (ROR = 1.53, CI = 1.10, 2.21), blood alkaline phosphatase increased (ROR = 14.60, CI = 9.28, 22.97) were possible AEs after romosozumab application. CONCLUSIONS: Our study provides an adverse reaction warning for the clinical application of romosozumab and provides a real-world disproportionality analysis data support for the possible AEs of romosozumab. |
ジャーナル名 | Expert opinion on drug safety |
Pubmed追加日 | 2022/10/1 |
投稿者 | Chen, Zepeng; Li, Ming; Li, Shuzhen; Li, Yuxi; Wu, Junyan; Qiu, Kaifeng; Yu, Xiaoxia; Huang, Lin; Chen, Guanghui |
組織名 | Department of Pharmacy, Sun-Yat-Sen Memorial Hospital, Sun Yat-sen University,;Guangzhou, Guangdong, China.;Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen Memorial;Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.;Department of Pharmacy, Liwan District Caihong Community Health Service Center, |
Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36178002/ |